Peter Mirkin, MD

Education

Dr. Peter Mirkin has been practicingpsychiatry for over 40 years, providing treatment for patients with mental health problems and addictions.

He is a consultant and affiliated provider at Spurwink Adult Behavioral Health in Portland, is the Medical Director of Oxford County Mental Health Services, is on the staff of Maine Health and is a Clinical Assistant Professor at Tufts University School of Medicine. He is Board Certified by the American Board of Psychiatry and Neurology, and licensed to prescribe Buprenorphine. He is a Life Member of the American Psychiatric Association and a Fellow of the American College of Medical Quality.

Dr. Mirkin graduated from the University of Cape Town Medical School.

Following psychiatric residencies in Cape Town and London, he completed an additional residency at the University of Connecticut Medical Center as well as a fellowship there in Alcohol Use Disorders at the NIMH funded Center for the Study of Alcoholism.

He subsequently served as the Director of Inpatient Psychiatry and
Assistant Director of the Psychiatry Department of Hartford Hospital in Connecticut. During that time, he completed an MBA at Rensselaer Polytechnic Institute.

After vacationing for some years in Maine, Dr. Mirkin moved here from Connecticut in 1996 with his family and has provided psychiatric services at Maine Medical Center, Counseling Services, Inc., Southern Maine Healthcare, Oxford County Mental Health Services and Spurwink Adult Behavioral Health Services. During this time he has also taught Tufts Medical students in a program designed to bring doctors-in-training to rural Maine.

As a part of his focus on managing treatment-resistant depression, Dr. Mirkin developed an interest in Transcranial Magnetic Stimulation and in 2011 completed a training program at the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center, Harvard Medical School.

Dr. Mirkin has collaborated with Dr. Edward J. Bilotti to establish TMS of Maine to provide Maine patients with expanded treatment options.